Japan To Compensate Hepatitis C Victims, Leave Drug Makers Liable (Japan)
This article was originally published in PharmAsia News
The Japanese government plans to enact legislation early in the new year to compensate some of an estimated 1,000 patients infected with hepatitis C after being given tainted blood products. The proposed bill would let the courts decide who would be eligible, as well as the fate of drug makers responsible for the suspect blood products. Under the bill being discussed by legislators, government compensation would be confined to patients given fibrinogen and hemostatic agents, but not to those infected through transfusions. Prime Minister Yasuo Fukuda apologized in person to four of the 200 people who filed suits. (Click here for more
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month
France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.